Adenovirus (AdV) based vectors have potential translational and commercial values and are currently studied as vectors for DNA transfer and vaccination. Adenovirus type 26 (AdV26) has fundamental differences in immunogenicity from other AdV vectors, which might give it advantage over other AdV serotypes in vaccine vector development. To the best of our knowledge there are no reports describing AdV26 entry pathway underlining the need for studying infection pathway used by AdV26. Accordingly, the main objectives of this study are investigating AdV26 receptor usage, binding, internalization, intracellular trafficking and AdV26 mediated induction of innate immune response. Our scientific objectives are novel, innovative and designed to generate new knowledge and opportunities for therapeutic advances in areas of unmet clinical need. Our technical objectives use state-of-the-art, span academic and industrial specialties creating cross sector knowledge and long lasting inter-sectoral benefits. With this project we will introduce new line of AdV vector research in our group that would position us on the exciting and cutting edge of AdV research. Herewith we will become part of long lasting network of industrial–academic partnership in adenovirus basic and translational research across Europe granting lasting collaborations and increasing possibilities for obtaining new grants in the future. We believe that outputs of our research will have considerable impact on the field through gaining new knowledge from which both academia and industry will benefit. Our group, whose establishment is proposed in this project, is the only research group that studies basic biology of adenovirus vectors in Croatia and this grant proposal represents continuation of active adenovirus research in Ruđer Bošković Institute.